ELISA. Western blot. Immunocytochemistry. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Buffer
PBS containing 0.02 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.
Target
PAK7
(P21 Protein (Cdc42/Rac)-Activated Kinase 7 (PAK7))
The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6. These proteins are not activated by Cdc42/Rac binding. PAK5 was initially identified as a kinase expressed primarily in brain that while possessing a kinase domain and GTPase binding domain similar to PAK4 and PAK6, is completely different from both. Expression of PAK5 in neural based cell lines resulted in neurite outgrowth suggesting that PAK5 may be involved in regulating the cytoskeletal changes necessary for promoting neurite outgrowth. Other experiments suggest that unlike the other PAKs, PAK5 may inhibit apoptosis by phosphorylating the Bcl-2 family member Bad.Synonyms: KIAA1264, PAK-5, PAK-7, Serine/threonine-protein kinase PAK 7, p21-activated kinase 5, p21-activated kinase 7